CR20170227A - Cromanos sutituidos y métodos para su uso - Google Patents
Cromanos sutituidos y métodos para su usoInfo
- Publication number
- CR20170227A CR20170227A CR20170227A CR20170227A CR20170227A CR 20170227 A CR20170227 A CR 20170227A CR 20170227 A CR20170227 A CR 20170227A CR 20170227 A CR20170227 A CR 20170227A CR 20170227 A CR20170227 A CR 20170227A
- Authority
- CR
- Costa Rica
- Prior art keywords
- formula
- methods
- compounds
- chronic
- substituted chromans
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La invención provee compuestos de fórmula (I) en donde R1, X, Y, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, m, y R¿ tienen cualquiera de los valores definidos en la memoria descriptiva, y sales farmacéuticamente aceptables de los mismos, que son útiles como agentes en el tratamiento de enfermedades y condiciones mediadas y moduladas por CFTR, que incluyen fibrosis quística, síndrome de Sjögren, insuficiencia pancreática, enfermedad pulmonar obstructiva crónica y enfermedad obstructiva crónica del flujo aéreo. También se proveen composiciones farmacéuticas que comprenden uno o más de los compuestos de fórmula (I).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462073573P | 2014-10-31 | 2014-10-31 | |
PCT/US2015/057837 WO2016069757A1 (en) | 2014-10-31 | 2015-10-28 | Substituted chromanes and method of use |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20170227A true CR20170227A (es) | 2017-12-04 |
Family
ID=55858309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20170227A CR20170227A (es) | 2014-10-31 | 2015-10-28 | Cromanos sutituidos y métodos para su uso |
Country Status (35)
Country | Link |
---|---|
US (3) | US9642831B2 (es) |
EP (1) | EP3212189B1 (es) |
JP (1) | JP6676646B2 (es) |
KR (3) | KR102462038B1 (es) |
CN (1) | CN107405337B (es) |
AR (1) | AR102492A1 (es) |
AU (1) | AU2015339336B2 (es) |
CA (2) | CA3191010A1 (es) |
CL (1) | CL2017001061A1 (es) |
CO (1) | CO2017005421A2 (es) |
CR (1) | CR20170227A (es) |
CY (1) | CY1123524T1 (es) |
DK (1) | DK3212189T3 (es) |
DO (1) | DOP2017000104A (es) |
EC (1) | ECSP17033565A (es) |
ES (1) | ES2830279T3 (es) |
HR (1) | HRP20201666T1 (es) |
HU (1) | HUE052373T2 (es) |
IL (1) | IL251996B (es) |
LT (1) | LT3212189T (es) |
MX (2) | MX366556B (es) |
MY (1) | MY194313A (es) |
PE (1) | PE20171106A1 (es) |
PH (1) | PH12017500797A1 (es) |
PL (1) | PL3212189T3 (es) |
PT (1) | PT3212189T (es) |
RS (1) | RS61267B1 (es) |
RU (1) | RU2718060C2 (es) |
SG (2) | SG10201803472QA (es) |
SI (1) | SI3212189T1 (es) |
TW (1) | TWI691496B (es) |
UA (1) | UA122965C2 (es) |
UY (1) | UY36379A (es) |
WO (1) | WO2016069757A1 (es) |
ZA (1) | ZA201703075B (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3708564A1 (en) | 2005-12-28 | 2020-09-16 | Vertex Pharmaceuticals Incorporated | A solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
MX342288B (es) | 2010-04-22 | 2016-09-23 | Vertex Pharma | Proceso para producir compuestos de cicloalquilcarboxamido-indol. |
ES2957761T3 (es) | 2014-04-15 | 2024-01-25 | Vertex Pharma | Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística |
US9840513B2 (en) | 2015-07-16 | 2017-12-12 | Abbvie S.Á.R.L. | Substituted tricyclics and method of use |
EP3359540A1 (en) | 2015-10-09 | 2018-08-15 | AbbVie S.À.R.L. | Novel compounds for treatment of cystic fibrosis |
SI3359541T1 (sl) | 2015-10-09 | 2021-01-29 | Abbvie Overseas S.A R.L. | N-sulfonirani pirazolo(3,4 b)piridin-6-karboksamidi in postopki uporabe |
TW201735769A (zh) | 2015-10-09 | 2017-10-16 | 盧森堡商艾伯維公司 | 經取代之吡唑并[3,4-b]吡啶-6-羧酸及使用方法 |
BR112018072047A2 (pt) * | 2016-04-26 | 2019-02-12 | AbbVie S.à.r.l. | moduladores da proteína reguladora de condutância transmembranar de fibrose cística |
US10138227B2 (en) | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
US9981910B2 (en) | 2016-10-07 | 2018-05-29 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
US10399940B2 (en) | 2016-10-07 | 2019-09-03 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
US20200123137A1 (en) | 2016-12-20 | 2020-04-23 | AbbVie S.à.r.l. | Deuterated cftr modulators and methods of use |
TW201831471A (zh) | 2017-02-24 | 2018-09-01 | 盧森堡商艾伯維公司 | 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法 |
CN106977483A (zh) * | 2017-06-02 | 2017-07-25 | 遵义医学院 | 一种二氟烷基取代的黄酮醇、异黄酮醇和香豆素类化合物的合成方法 |
EP3645538A1 (en) * | 2017-06-28 | 2020-05-06 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of indoleamine 2,3-dioxygenase |
US10988454B2 (en) | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
AU2018345523B2 (en) * | 2017-10-02 | 2021-10-21 | Merck Sharp & Dohme Llc | Chromane monobactam compounds for the treatment of bacterial infections |
WO2019193062A1 (en) | 2018-04-03 | 2019-10-10 | Abbvie S.Á.R.L | Substituted pyrrolidines and their use |
US11345691B2 (en) | 2019-06-03 | 2022-05-31 | AbbVie Global Enterprises Ltd. | Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
WO2021011327A1 (en) | 2019-07-12 | 2021-01-21 | Orphomed, Inc. | Compound for treating cystic fibrosis |
CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
EP4274828A1 (en) | 2021-01-06 | 2023-11-15 | AbbVie Global Enterprises Ltd. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
WO2022150173A1 (en) | 2021-01-06 | 2022-07-14 | AbbVie Global Enterprises Ltd. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
CN113234113B (zh) * | 2021-05-31 | 2023-09-01 | 江西师范大学 | 一种构建1,2-顺式-2-硝基-葡萄糖苷和半乳糖糖苷的方法 |
CN113372318A (zh) * | 2021-07-02 | 2021-09-10 | 贵州中医药大学 | 7-甲氧基-4’-甲酸甲酯二氢黄酮的制备方法及装置 |
TW202333699A (zh) | 2022-02-03 | 2023-09-01 | 美商維泰克斯製藥公司 | 囊腫纖維化之治療方法 |
WO2023150236A1 (en) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol |
WO2023154291A1 (en) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2023224931A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2024056791A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators |
WO2024056798A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
US20240164146A1 (en) | 2022-11-11 | 2024-05-16 | Samsung Display Co., Ltd. | Display device and electronic device having the same |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
WO2005075435A1 (en) | 2004-01-30 | 2005-08-18 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
EP1912983B1 (en) | 2005-08-11 | 2011-06-08 | Vertex Pharmaceuticals, Inc. | Modulators of cystic fibrosis transmembrane conductance regulator |
US20120232059A1 (en) | 2005-11-08 | 2012-09-13 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette Transporters |
SI2395002T1 (sl) | 2005-11-08 | 2014-10-30 | Vertex Pharmaceuticals Incorporated | Farmacevtski sestavek, vsebujoč heterociklični modulator prenašalcev z ATP-vezavno kaseto |
CN103214450B (zh) | 2005-12-28 | 2016-10-05 | 弗特克斯药品有限公司 | 作为atp-结合盒转运蛋白调节剂的1-(苯并[d][1,3]间二氧杂环戊烯-5-基)-n-(苯基)环丙烷-甲酰胺衍生物 |
US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
EP2007756B1 (en) | 2006-04-07 | 2015-08-26 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
WO2008127399A2 (en) | 2006-11-03 | 2008-10-23 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as cftr modulators |
US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
JP5497633B2 (ja) | 2007-05-09 | 2014-05-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | Cftrのモジュレーター |
ES2658064T3 (es) | 2007-11-16 | 2018-03-08 | Vertex Pharmaceuticals Incorporated | Moduladores de isoquinolina de transportadores de casete de unión a ATP |
EA201070699A1 (ru) * | 2007-12-07 | 2011-02-28 | Вертекс Фармасьютикалз Инкорпорейтед | Композиции 3-(6-(1-2,2-дифторбензо[d][1,3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты |
CA2931134C (en) | 2008-02-28 | 2019-07-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
EP2980077B1 (en) | 2008-03-31 | 2020-05-06 | Vertex Pharmaceuticals Incorporated | Pyridyl derivatives as cftr modulators |
WO2011008931A2 (en) | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders |
ES2604105T3 (es) * | 2010-03-25 | 2017-03-03 | Vertex Pharmaceuticals Incorporated | Formula cristalina de (r) -1 (2,2- difluorobenzo [d] [1,3] dioxol - 5yl) - n- (1- (2,3 - dihidroxipropil) - 6 - fluoro - 2- (1 - hydroxy-2-metilpropan-2il) -1h-indol-5il) cyclopropanecarboxamida |
AR087274A1 (es) * | 2011-07-22 | 2014-03-12 | Actelion Pharmaceuticals Ltd | Derivados de amidas heterociclicas como antagonistas de receptores p2x7 |
US9790219B2 (en) * | 2014-03-13 | 2017-10-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
WO2017060880A1 (en) * | 2015-10-09 | 2017-04-13 | AbbVie S.à.r.l. | Potentiator-corrector combinations useful in the treatment of cystic fibrosis |
EP3359540A1 (en) * | 2015-10-09 | 2018-08-15 | AbbVie S.À.R.L. | Novel compounds for treatment of cystic fibrosis |
-
2015
- 2015-10-28 CA CA3191010A patent/CA3191010A1/en active Pending
- 2015-10-28 PL PL15854320T patent/PL3212189T3/pl unknown
- 2015-10-28 SG SG10201803472QA patent/SG10201803472QA/en unknown
- 2015-10-28 MX MX2017005681A patent/MX366556B/es active IP Right Grant
- 2015-10-28 RU RU2017118552A patent/RU2718060C2/ru active
- 2015-10-28 KR KR1020177014811A patent/KR102462038B1/ko active IP Right Grant
- 2015-10-28 SI SI201531390T patent/SI3212189T1/sl unknown
- 2015-10-28 WO PCT/US2015/057837 patent/WO2016069757A1/en active Application Filing
- 2015-10-28 CR CR20170227A patent/CR20170227A/es unknown
- 2015-10-28 RS RS20201328A patent/RS61267B1/sr unknown
- 2015-10-28 UA UAA201705277A patent/UA122965C2/uk unknown
- 2015-10-28 CA CA2965981A patent/CA2965981C/en active Active
- 2015-10-28 ES ES15854320T patent/ES2830279T3/es active Active
- 2015-10-28 KR KR1020237008262A patent/KR20230040378A/ko not_active Application Discontinuation
- 2015-10-28 US US14/925,649 patent/US9642831B2/en active Active
- 2015-10-28 JP JP2017542792A patent/JP6676646B2/ja active Active
- 2015-10-28 HU HUE15854320A patent/HUE052373T2/hu unknown
- 2015-10-28 LT LTEP15854320.7T patent/LT3212189T/lt unknown
- 2015-10-28 KR KR1020227037449A patent/KR102509720B1/ko active Application Filing
- 2015-10-28 DK DK15854320.7T patent/DK3212189T3/da active
- 2015-10-28 EP EP15854320.7A patent/EP3212189B1/en active Active
- 2015-10-28 PE PE2017000764A patent/PE20171106A1/es unknown
- 2015-10-28 AU AU2015339336A patent/AU2015339336B2/en active Active
- 2015-10-28 CN CN201580071713.XA patent/CN107405337B/zh active Active
- 2015-10-28 SG SG11201703391VA patent/SG11201703391VA/en unknown
- 2015-10-28 PT PT158543207T patent/PT3212189T/pt unknown
- 2015-10-28 MY MYPI2017701450A patent/MY194313A/en unknown
- 2015-10-30 UY UY0001036379A patent/UY36379A/es unknown
- 2015-10-30 TW TW104135934A patent/TWI691496B/zh active
- 2015-10-30 AR ARP150103536A patent/AR102492A1/es unknown
-
2017
- 2017-03-23 US US15/467,737 patent/US20170190693A1/en not_active Abandoned
- 2017-04-26 DO DO2017000104A patent/DOP2017000104A/es unknown
- 2017-04-27 PH PH12017500797A patent/PH12017500797A1/en unknown
- 2017-04-27 IL IL251996A patent/IL251996B/en active IP Right Grant
- 2017-04-28 MX MX2019008361A patent/MX2019008361A/es unknown
- 2017-04-28 CL CL2017001061A patent/CL2017001061A1/es unknown
- 2017-05-04 ZA ZA2017/03075A patent/ZA201703075B/en unknown
- 2017-05-30 CO CONC2017/0005421A patent/CO2017005421A2/es unknown
- 2017-05-31 EC ECIEPI201733565A patent/ECSP17033565A/es unknown
-
2018
- 2018-12-19 US US16/225,991 patent/US20190127356A1/en not_active Abandoned
-
2020
- 2020-10-15 HR HRP20201666TT patent/HRP20201666T1/hr unknown
- 2020-10-30 CY CY20201101027T patent/CY1123524T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2017005421A2 (es) | Cromanos sustituidos y métodos para su uso | |
CL2018000911A1 (es) | Pirazolo[3,4-b]piridin-6-carboxamidas n-sulfoniladas y método de uso | |
DOP2018000020A (es) | Tricíclicos sustituidos y método para usarlos | |
CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
CL2015001358A1 (es) | Potenciadores del cftr deuterados | |
CL2016001543A1 (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas. | |
PE20210470A1 (es) | Macrociclos con grupos p2' heterociclicos como inhibidores del factor xia | |
UY35675A (es) | Derivados sustituidos de quinazolin-4-ona | |
CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
CL2015002897A1 (es) | Inhibidores de bace1 | |
ES2969344T3 (es) | Composiciones de profármaco de alta penetración y composición farmacéutica del mismo para el tratamiento de afecciones pulmonares | |
EA201790046A1 (ru) | Бензоксазиноновые амиды в качестве модуляторов минералокортикоидного рецептора | |
MD3500241T2 (ro) | Terapie combinată pentru BPOC | |
CL2016002839A1 (es) | Derivados de carboxamida | |
DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
CL2016002267A1 (es) | Ureas asimétricas p-sustituidas y usos médicos de las mismas | |
CL2015003431A1 (es) | Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales | |
UY36732A (es) | Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet | |
CU20180044A7 (es) | Derivados novedosos de diamino piridina | |
CY1121235T1 (el) | Νεα χρηση toy ν,ν-δι-2-μερκαπτοαιθυλο ισοφθαλαμιδιου | |
DOP2016000325A (es) | Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas |